Lupin and SunPharma Launch Generic Favipiravir to Treat Mild to Moderate COVID-19 in India

 Lupin and SunPharma Launch Generic Favipiravir to Treat Mild to Moderate COVID-19 in India

Lupin and SunPharma Launch Generic Favipiravir to Treat Mild to Moderate COVID-19

Shots:

  • Lupin has launched favipiravir in India under the brand name ‘Covihalt’ for the treatment of mild to moderate COVID-19
  • Covihalt will be available as 200mg tablets in the form of a strip of 10 tablets, priced at $0.65 (₹49/tablet) and has received DCGI authorization for emergency use
  • Additionally, SunPharma has launched antiviral drug favipiravir under the brand name ‘FluGuard’ to treat mild to moderate cases of COVID-19, at ₹35/tablet in India

Lupin, SunPharma ­to­ read full press release/ article  | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post